Blood biomarkers may let ICU patients stop antifungals earlier

NCT ID NCT03538912

Completed Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using blood biomarkers (beta-D-glucan and mannan) can help doctors safely stop antifungal drugs earlier in critically ill patients suspected of a fungal infection. 192 ICU patients were randomly assigned to either a biomarker-guided strategy or standard care. The goal was to see if the biomarker approach could reduce unnecessary antifungal use without increasing the risk of death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: biomarker-guided strategy (blood tests for fungal markers)
What this could lead to: If successful, this approach could reduce unnecessary antifungal use in ICU patients, lowering side effects and costs without increasing deaths.
What could go wrong: This is a completed trial with 192 patients, so results are available but may not apply to all ICU settings. The biomarker strategy might not be as safe in patients with weak immune systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

candidiasis, invasive disseminated candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE CANDIDIASIS

Contacts and locations

Locations

CH ARRAS

Arras, France
CH Dunkerque

Dunkirk, France
CH Roubaix

Roubaix, France
CH de DOUAI

Douai, France
CHU de Rouen

Rouen, France
Centre Hospitalier Dr Schaffner

Lens, France
Centre hospitalier de valenciennes

Valenciennes, France
Ch Dr.Schaffner de Lens

Lens, France
Ch Tourcoing

Tourcoing, France
Hôpital Roger Salengro, CHU

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.